VaxCell Biotherapeutics Co.
Latest round
- Series B
Last raised
- Jun 2018
Total raised
- $14M
Investors
- 8
About VaxCell Biotherapeutics Co.
, Ltd. operates as a biotech company that focuses on patient-specific total solution anti-cancer immunotherapy R&D. In 2020, the company was listed on the KOSDAQ. The company's business can be categorized into the Vax-NK Platform, Vax-DC Platform, Vax-CARs Platform, and Vaxleukin-15. The company has developed immune cell therapy using natural killer cells and dendritic cells and is conducting phase 2 clinical trials.
Who invested in VaxCell Biotherapeutics Co.
8 investors across 2 rounds
See all investors in VaxCell Biotherapeutics Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VaxCell Biotherapeutics Co.
Who invested in VaxCell Biotherapeutics Co.?
VaxCell Biotherapeutics Co. has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VaxCell Biotherapeutics Co. raised?
VaxCell Biotherapeutics Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did VaxCell Biotherapeutics Co. last raise money?
VaxCell Biotherapeutics Co.'s most recent round on record is a Series B, in Jun 2018.
What does VaxCell Biotherapeutics Co. do?
VaxCell Biotherapeutics Co. is a biotechnology company.
Where is VaxCell Biotherapeutics Co. headquartered?
VaxCell Biotherapeutics Co. is headquartered in South Korea.
Which VCs invest in companies like VaxCell Biotherapeutics Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at VaxCell Biotherapeutics Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like VaxCell Biotherapeutics Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.